Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Myriad Genetics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -6.87%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Myriad Genetics's 3-Year ROIIC % or its related term are showing as below:
STU:MYD's 3-Year ROIIC % is ranked worse than 61.27% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs STU:MYD: -6.87
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Myriad Genetics 3-Year ROIIC % Related Terms
Myriad Genetics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Myriad Genetics (STU:MYD) has a 3-Year ROIIC % of -6.87 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #125 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 61.3%.
Is Myriad Genetics' 3-Year ROIIC % too high?
Myriad Genetics' current 3-Year ROIIC % is -6.87. Based on the distribution chart, Myriad Genetics ranks #125 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' 3-Year ROIIC % compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #125 out of 204 companies for 3-Year ROIIC %. This places Myriad Genetics in the lower half of its industry. The industry median 3-Year ROIIC % is 0.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current 3-Year ROIIC % is -6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.34, compared to a current price of €5.19 — trading 61.1% below its estimated fair value. The current 3-Year ROIIC % is -6.87. Myriad Genetics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current 3-Year ROIIC % is -6.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.19 is trading 61.1% below its estimated GF Value™ of €13.34.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
3-Year ROIIC %: -6.87
GF Value™: €13.34 vs. price of €5.19 (61.1% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
59GF Score
Get the complete analysis for STU:MYD
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
